Document resource
The question of whether children with gender dysphoria should have access to puberty blockers and masculinising/feminising hormones is a highly politicised issue. In countries like France, Finland, Germany, Sweden and Switzerland, high-ranking panels were commissioned to assess the current clinical practice. When in April 2024 the British National Health Service (NHS) published the Cass Review, commissioned as ‘Independent review on gender identity services for children and young people’,1 its recommendations against the clinical use of puberty blockers and hormones were broadly noted. Following the Cass Review, the NHS published a new clinical policy ‘that prevents the prescribing of Puberty Suppressing Hormones to children and young people under 18 years of age’. Also, ‘extreme caution’ was recommended regarding the prescription of masculinising/feminising hormones for persons under the age of 18.2